PYM
Creates natural supplements with science-backed ingredients to boost mood and neurotransmitter health.
Website: https://youcanpym.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | PYM (Prepare Your Mind) |
| Tagline | Natural supplements with science-backed ingredients to support mood and neurotransmitter health |
| Headquarters | Los Angeles, California |
| Founded | 2018 |
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech (mental wellness / supplements) |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Co-Founders (2): Zak Williams, Olivia June |
| Funding Label | Seed |
| Total Disclosed | ~$1,000,000 [Inc] |
Links
PUBLIC
- Website: https://youcanpym.com/
- LinkedIn: https://www.linkedin.com/company/pyminc
- Lead investor portfolio listing: https://adaptvc.com/companies
Executive Summary
PUBLIC
PYM is a Los Angeles-based direct-to-consumer mental wellness brand selling amino-acid-based chewables positioned as a daily support tool for mood and stress, founded in 2018 by Zak Williams and Olivia June [Crunchbase]. The company sits at an intersection that has drawn meaningful consumer attention over the past five years: the destigmatization of mental health, the mainstreaming of nutraceuticals, and a generation of consumers willing to try non-prescription alternatives before, or alongside, clinical care. Zak Williams launched the company after the 2014 death of his father, the actor Robin Williams, and has built much of PYM's public identity around mental health advocacy [Fortune, 2023]. The product line centers on "Mood Chews" formulated with amino acids, vitamins, and minerals intended to support neurotransmitter pathways [LinkedIn]. The disclosed capitalization is modest: roughly $1 million reported around the launch of a new product [Inc], with Adapt VC named among backers [Adapt VC]. The founding team pairs a CEO with a Columbia MBA and an entertainment-industry network [Crunchbase] [The Org] with a co-founder who previously built community and studio programs at RocketSpace and founded VINA [Crunchbase]. Over the next 12 to 18 months, the variables most worth watching are SKU expansion, retail distribution beyond the DTC site, and whether PYM converts founder-led media reach into repeat purchase economics that justify a priced equity round.
Data Accuracy: YELLOW -- Founding details and funding figure corroborated by Crunchbase, Inc., and Fortune; growth metrics not publicly disclosed.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Direct-to-Consumer |
| Industry / Vertical | Healthtech, mental wellness supplements |
| Technology Type | Biotech / Life Sciences (nutraceutical formulation) |
| Geography | North America |
| Founding Team | Two co-founders (spousal team) |
| Funding | ~$1M disclosed, Seed |
Company Overview
PUBLIC
PYM, short for "Prepare Your Mind," was founded in 2018 in Los Angeles by Zak Williams and Olivia June [Crunchbase]. The origin story is unusually personal and well-documented for a company at this stage: Williams has spoken publicly about building the company in response to his own struggles with anxiety and depression following his father Robin Williams's death in 2014, and has framed PYM as part of a broader personal commitment to mental health advocacy [Fortune, 2023]. Olivia June, who is married to Williams and previously founded the friendship app VINA, collaborated on the early formulation work after what the company describes as her own experience with mood regulation through amino acid therapy [PYM Website] [Crunchbase].
The company has stayed deliberately narrow on product surface area. Its flagship is a chewable supplement marketed under the "Mood Chews" line, sold through the youcanpym.com storefront and reviewed in consumer-facing outlets such as Honest Brand Reviews and The Quality Edit [Honest Brand Reviews] [The Quality Edit]. Williams has used speaking platforms, including Fortune's Brainstorm Health conference, to discuss the company's positioning at the intersection of consumer wellness and mental health [Fortune, 2023].
Publicly identified milestones are limited. Inc. reported a roughly $1 million raise tied to a new product launch [Inc], and Adapt VC lists PYM in its portfolio [Adapt VC]. Beyond that, the company has not disclosed revenue, unit volume, retail partnerships, or subsequent priced rounds in the captured public record. The legal entity name and state of incorporation are not publicly available in the sources reviewed.
Data Accuracy: YELLOW -- Founding story and team confirmed by Fortune, Crunchbase, and the company website; corporate registration details not in the public record.
Product and Technology
MIXED
PYM's product is a consumer supplement, not a software platform, so the relevant technology question is formulation rather than stack. The company describes its chews as built around amino acids, vitamins, and minerals selected to support neurotransmitter health [LinkedIn]. Crunchbase characterizes PYM as working with "neuroscientists and nutritional psychiatrists" to develop a "personal mental hygiene solution" [Crunchbase], language that reflects the company's positioning as adjacent to, rather than a substitute for, clinical mental health care.
Third-party consumer reviews provide the clearest external read on the product experience. Honest Brand Reviews and The Quality Edit both cover the Mood Chews format, packaging, and taste, and describe the product as an over-the-counter daily-use chew rather than a clinical intervention [Honest Brand Reviews] [The Quality Edit]. The product is regulated in the United States as a dietary supplement, which means it is not subject to FDA pre-market efficacy review; that regulatory framing is standard for the category and shapes both the marketing claims the company can make and the evidentiary burden it carries with consumers and retailers.
No proprietary delivery technology, patent filing, or manufacturing facility has been disclosed in the captured sources, and PYM has not surfaced public engineering or formulation roles that would indicate the shape of an internal R&D function (no open job postings were surfaced from careers page or major ATS hosts). Investors evaluating the technology layer should treat the differentiation as resting on brand, founder narrative, and ingredient curation rather than on defensible IP.
Data Accuracy: ORANGE -- Product description corroborated by company site, LinkedIn, and two consumer review outlets; formulation IP and manufacturing partners not publicly disclosed.
Market Research and Opportunity
PUBLIC
The market PYM is selling into is one where consumer demand has clearly arrived ahead of clinical consensus. United States adults reporting symptoms of anxiety or depression climbed sharply during and after the pandemic, and over-the-counter mood and stress products have become one of the fastest-growing shelf categories in mass and natural retail. Specific TAM, SAM, and SOM figures from a named third-party report are not present in the captured research for PYM, so the sizing discussion below relies on directional context from analogous markets and on what is observable in the cited press.
The demand drivers most relevant to PYM are three. First, destigmatization: Williams's own public advocacy is one example of a broader cultural shift in which discussing mood and anxiety has moved into mainstream consumer conversation [Fortune, 2023]. Second, the bottleneck in clinical access: wait times for therapists and psychiatrists in major U.S. metros routinely run weeks to months, which has pushed consumers toward self-directed, lower-friction options. Third, the maturation of the functional supplements category, where amino acid blends, adaptogens, and nootropics have moved from niche retailers into Whole Foods, Target, and Amazon's main supplement aisles.
Adjacent and substitute markets matter for how PYM is valued. On one side sit telehealth-prescribed mental health platforms (Cerebral, Talkiatry, Hims & Hers Mental Health), which compete for the same consumer attention but address a more clinically severe segment. On the other side sit pure consumer brands in functional wellness (Olly, Calm-branded gummies, Moon Juice, Recess) that compete directly for shelf space and consumer trial. The strategic question is whether PYM is best understood as a healthcare brand with a wellness wrapper or a wellness brand with a healthcare narrative; valuation comps differ by an order of magnitude between those framings.
Regulatory posture is the macro variable most likely to reshape the category. The FDA has signaled increasing scrutiny of supplement marketing claims that edge into disease treatment language, and class-action litigation around "mood" and "stress" claims has risen. PYM's public messaging has stayed on the wellness side of that line in the materials reviewed [PYM Website] [Honest Brand Reviews], which is consistent with category best practice but is a discipline the company will need to maintain as it scales.
| Sizing reference | Figure | Source |
|---|---|---|
| PYM disclosed capital raised (around new product launch) | ~$1,000,000 | [Inc] |
from the available numbers is narrow but honest: the only PYM-specific figure in the public record is the disclosed raise, and any market-size assertions beyond that should be treated as analogous-category context rather than company-validated TAM.
Data Accuracy: ORANGE -- Category context is analyst commentary; the only PYM-specific number is the Inc.-reported raise.
Competitive Landscape
MIXED
PYM competes in a crowded consumer wellness shelf where brand, founder narrative, and retail distribution matter more than formulation novelty.
The segment can be mapped into three groups. The first is mass-market functional supplement brands such as Olly (acquired by Unilever in 2019), Natrol, and the Calm-branded gummy line; these players have deep retail relationships, scale manufacturing, and the ability to outspend a seed-stage challenger on shelf placement and search. The second is venture-backed DTC wellness brands that have built around a specific use case (sleep, stress, focus) and a strong founder voice, including Recess, Moon Juice, and Apothékary; these are PYM's closest peers in positioning, audience, and price point. The third is the telehealth-and-prescription cohort, including Hims & Hers's mental health line and Cerebral, which competes for the same anxious consumer but routes them toward SSRIs and clinician visits rather than chewables.
Where PYM has a defensible edge today, it is on narrative and earned media rather than on distribution or IP. Founder-led press in Fortune, Inc., and the San Francisco Chronicle gives the brand a story that is genuinely difficult to replicate, and Williams's mental health advocacy work compounds that asset every time he speaks publicly [Fortune, 2023] [Inc] [San Francisco Chronicle]. That edge is real but perishable: founder-driven press converts into retention only if product experience and repeat purchase rates hold, and there is no public data confirming either.
Where PYM is most exposed is on capital and distribution. A roughly $1 million disclosed raise [Inc] is a fraction of what Olly, Recess, or Hims have deployed against the same consumer, and physical retail in the supplement aisle is largely a slotting-fee game that rewards balance sheet over storytelling. The most plausible 18-month scenario splits along that axis. Winner if PYM secures a national specialty retail partner (a Whole Foods, Sprouts, or Erewhon rollout) and uses that to anchor a priced Series A, converting founder reach into shelf velocity. Loser if the category's larger players launch a competing "mood chew" SKU and out-merchandise PYM at point of sale before it can lock in a defensible retail footprint.
Data Accuracy: ORANGE -- Competitor set is analyst-identified from the broader category; no head-to-head share data is publicly disclosed for PYM.
Opportunity
PUBLIC
If PYM executes, the prize is becoming the default consumer brand for everyday mental wellness, a category that has produced nine-figure exits in adjacent verticals and has not yet crowned a clear winner.
The headline opportunity is that PYM becomes the Olly of mental wellness: a recognizable, multi-SKU, mass-distributed consumer brand specifically associated with mood and stress support, sold across DTC, Amazon, and national specialty and grocery retail. The cited evidence makes that outcome reachable rather than aspirational for two reasons. First, the founder has demonstrable, repeatable access to top-tier consumer and business press on a topic he is personally credible discussing [Fortune, 2023] [Inc] [San Francisco Chronicle], which is the single hardest input to manufacture in DTC wellness. Second, the product format (a daily chew at a consumer-friendly price point) is one that has historically traveled well from DTC into mass retail in adjacent categories such as sleep, immunity, and prenatal.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Specialty retail breakout | PYM lands a national specialty grocery or beauty rollout (Whole Foods, Sprouts, Erewhon, or Sephora wellness) and uses sell-through data to raise a priced Series A | A merchandising buyer commits to a chain-wide planogram set | Founder media reach and category tailwinds in mood support are documented [Fortune, 2023] |
| Strategic acquisition | A consumer health incumbent (Unilever, P&G Health, Church & Dwight, Bayer Consumer) acquires PYM to enter the mental wellness shelf | A category-defining quarter of DTC growth or a retail data point that signals category leadership | Olly's 2019 acquisition by Unilever established the playbook for incumbents buying functional-wellness DTC brands |
| Platform brand expansion | PYM extends from chews into adjacent SKUs (sleep, focus, hormonal mood support) and becomes a multi-product mental wellness house brand | A successful second-product launch with retained DTC subscribers | Adapt VC's portfolio thesis backs consumer brands building beyond a single SKU [Adapt VC] |
What compounding looks like for PYM is the classic consumer brand flywheel layered on top of a founder media engine. Each press hit and speaking appearance from Williams drives top-of-funnel awareness at near-zero customer acquisition cost; subscription DTC purchases generate first-party data on which messaging and which use cases convert; that data informs both the second SKU and the pitch to retail buyers; retail placement reduces blended CAC further and validates the brand for the next wave of press. The flywheel is observable in the press cadence already, though there is no public data confirming subscription retention or repeat purchase rates.
On the size of the win: Unilever's reported acquisition of Olly Nutrition in 2019 was widely covered as a strategic entry into the functional gummy category and is the most relevant comparable for a DTC-led, chewable-format wellness brand reaching scale. If PYM were to reach a comparable position in the mental wellness sub-category, the outcome could be a strategic exit in the high nine to low ten figures (scenario, not a forecast). A more modest but still meaningful outcome is a profitable, founder-led specialty brand with $30 to $100 million in annual revenue that trades at consumer-staples multiples; that path requires less capital and is more consistent with the company's current disclosed funding posture.
Data Accuracy: YELLOW -- Scenarios are analyst-constructed from category comparables; only the founder media footprint and disclosed raise are directly evidenced in the cited sources.
Sources
PUBLIC
[Crunchbase] PYM - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/pym
[Crunchbase] Zak Williams - Co-Founder and CEO @ PYM | https://www.crunchbase.com/person/zak-williams
[LinkedIn] PYM | LinkedIn | https://www.linkedin.com/company/pyminc
[Fortune, 2023] Robin Williams's son is dedicating his life to improving mental health | https://fortune.com/well/2023/05/01/robin-williams-son-zak-williams-mental-health-journey/
[Fortune, 2023] Brainstorm Health 2023 - Prepare Your Mind: The Journey To Launch A Mental Health Startup | https://fortune.com/videos/watch/brainstorm-health-2023---prepare-your-mind:-the-journey-to-launch-a-mental-health-startup-/475e0eaf-43a4-4ab4-a6b7-22ee7e10bd71
[San Francisco Chronicle] Robin Williams' son teams up with S.F. startup to use AI as mental health resource | https://www.sfchronicle.com/entertainment/article/robin-zak-williams-21309661.php
[Substack] Interview with Zak Williams, CEO and Co-Founder of Prepare Your Mind | https://cluesdotlife.substack.com/p/interview-with-zak-williams-ceo-and
[Honest Brand Reviews] PYM Mood Chews Review | https://www.honestbrandreviews.com/reviews/pym-mood-chews-review/
[PYM] Our Story | https://youcanpym.com/pages/our-story
[The Quality Edit] PYM Mood Chew Review | https://www.thequalityedit.com/articles/pym-mood-chew-review
[PYM] PYM (Prepare Your Mind) storefront | https://youcanpym.com/
[Inc] Robin Williams's Son Zak Battled Depression Too. Now His Mental Health Startup Has a New Product and $1 Million | https://www.inc.com/lindsay-blakely/zak-williams-pym-mental-health-wellness-startup.html
[Adapt VC] A distinctive portfolio | https://adaptvc.com/companies
[The Org] Zak Williams profile | https://theorg.com/
[Milken Institute] Zak Williams speaker profile | https://milkeninstitute.org/
Articles about PYM
- PYM Is Betting Amino Acid Chews Can Sit Next to the Antidepressant — Zak Williams's Los Angeles supplement company is courting adults with everyday mood and anxiety symptoms, with $1M in seed capital and a DTC wedge.